Skip to content
  • en
  • ms

  • NADA Profile
    • Corporate Info
      • Message from The Director General of National Anti-Drugs Agency (NADA)
      • Top Management
      • Chief Information Officer (CIO)
      • About NADA
      • History Of NADA
      • Vision, Mission and Objectives
      • Client’s Charter
      • Client Charter Achievement Report
    • Policies, Acts & Circulars
      • State Drug Policy
      • Drugs-Related Act
      • NADA Financial Management Guidelines
      • ICT Management Circulars and Policies
      • Anti-Drug Agency Training Policy (DLAADK)
      • AADK Disciplinary Management Guide
      • Organizational Anti-Corruption Plan (OACP) AADK 2020-2024
      • NADA Anti-Corruption Policy
    • Divisions And Units
      • Treatment, Medicational And Rehabilitation Division
      • Enforcement And Security Division
      • Management Service Division
      • Information Technology And Communication Division
      • Policy, Planning And Research Division
      • Legal Advisory Unit
      • Media And Corporate Communication Unit
      • International Unit
      • Integrity Unit
      • MGDN Secretariat Unit
      • NADA Training Centre
    • Directory
      • Headquarter
      • NADA State Office
      • NADA District Office
      • Rehabilitation Centre
      • NADA Service Centre
      • Community House
      • Client Integration Centre (CIC)
      • Anti-Drugs Border Unit (UAS)
      • NADA Training Centre
  • Services
    • Treatment & Rehabilitation
      • Institution Based Treatment And Rehabilitation
      • Community Based Treatment And Rehabilitation
      • NADA’s Tele Hello
    • Prevention
      • Public Awareness and Anti-Drugs Campaigns
      • High Risk Areas Of Drugs Addiction
      • Drugs Free Family
      • Drug Free Educational Institutions
      • Drugs Free Workplace
      • Drugs Free Community
    • Enforcement
      • Complaints on Drug Problems
      • Hotline Operations Center (PGH)
      • Compliance with the Person Under Surveillance
  • Public
    • General
      • Advertisement/Tender and Quotation Statement
      • Drugs Statistics
      • NADA Research Grant
      • Federal Government Gazette
      • List of Private Drugs Rehabilitation Centers
      • Complaints and Feedback
      • e-Participation Policy
    • Online Services
      • Application for Anti-Drugs SKUAD Membership
      • Application for Anti-Drugs Exhibition
      • e-DrugNews
      • Library of AADK
      • Integrity Complain
      • The Malaysian Anti-Drugs Journal
    • Media & Publishing
      • AADK TV
      • Infographic
      • Informations On Drugs
      • Annual Report
      • Publishing
      • Integrity Lens
      • NADA Scientific Research Study
    • FAQ
      • FAQ : Enforcement And Security
      • FAQ : Pusat Pemulihan Penagihan Narkotik (PUSPEN)
      • FAQ : NADA Service Centre
      • FAQ : Community House
      • FAQ : Client Integration Centre (CIC)
      • FAQ : Private Drug Rehabilitation Centre (PPDP)
      • FAQ : Antidrugs SKUAD
  • NADA Staff
    • Login
      • AADK Official Email
  • en
  • ms

  • NADA Profile
    • Corporate Info
      • Message from The Director General of National Anti-Drugs Agency (NADA)
      • Top Management
      • Chief Information Officer (CIO)
      • About NADA
      • History Of NADA
      • Vision, Mission and Objectives
      • Client’s Charter
      • Client Charter Achievement Report
    • Policies, Acts & Circulars
      • State Drug Policy
      • Drugs-Related Act
      • NADA Financial Management Guidelines
      • ICT Management Circulars and Policies
      • Anti-Drug Agency Training Policy (DLAADK)
      • AADK Disciplinary Management Guide
      • Organizational Anti-Corruption Plan (OACP) AADK 2020-2024
      • NADA Anti-Corruption Policy
    • Divisions And Units
      • Treatment, Medicational And Rehabilitation Division
      • Enforcement And Security Division
      • Management Service Division
      • Information Technology And Communication Division
      • Policy, Planning And Research Division
      • Legal Advisory Unit
      • Media And Corporate Communication Unit
      • International Unit
      • Integrity Unit
      • MGDN Secretariat Unit
      • NADA Training Centre
    • Directory
      • Headquarter
      • NADA State Office
      • NADA District Office
      • Rehabilitation Centre
      • NADA Service Centre
      • Community House
      • Client Integration Centre (CIC)
      • Anti-Drugs Border Unit (UAS)
      • NADA Training Centre
  • Services
    • Treatment & Rehabilitation
      • Institution Based Treatment And Rehabilitation
      • Community Based Treatment And Rehabilitation
      • NADA’s Tele Hello
    • Prevention
      • Public Awareness and Anti-Drugs Campaigns
      • High Risk Areas Of Drugs Addiction
      • Drugs Free Family
      • Drug Free Educational Institutions
      • Drugs Free Workplace
      • Drugs Free Community
    • Enforcement
      • Complaints on Drug Problems
      • Hotline Operations Center (PGH)
      • Compliance with the Person Under Surveillance
  • Public
    • General
      • Advertisement/Tender and Quotation Statement
      • Drugs Statistics
      • NADA Research Grant
      • Federal Government Gazette
      • List of Private Drugs Rehabilitation Centers
      • Complaints and Feedback
      • e-Participation Policy
    • Online Services
      • Application for Anti-Drugs SKUAD Membership
      • Application for Anti-Drugs Exhibition
      • e-DrugNews
      • Library of AADK
      • Integrity Complain
      • The Malaysian Anti-Drugs Journal
    • Media & Publishing
      • AADK TV
      • Infographic
      • Informations On Drugs
      • Annual Report
      • Publishing
      • Integrity Lens
      • NADA Scientific Research Study
    • FAQ
      • FAQ : Enforcement And Security
      • FAQ : Pusat Pemulihan Penagihan Narkotik (PUSPEN)
      • FAQ : NADA Service Centre
      • FAQ : Community House
      • FAQ : Client Integration Centre (CIC)
      • FAQ : Private Drug Rehabilitation Centre (PPDP)
      • FAQ : Antidrugs SKUAD
  • NADA Staff
    • Login
      • AADK Official Email
Agensi Antidadah Kebangsaan > NADA's News

NADA’s News

MTMD: Three proposal were approved by the Negeri Sembilan Government

14 March 2023

Seberang Perai Utara Anti-Drugs Squad Volunteers host The Hijaukan KBT Cycling

12 March 2023

PCDM trust assurance, towards NADA clients negative stigma

10 March 2023

KPI: MRT NADA exceeded target goal

9 March 2023

75 percent client recovery rate, target group – TKPO

7 March 2023

‘Young Leaders Talk’ program with the Chief Minister of Sabah

6 March 2023

MYDPS: Early detection, OYDS

6 March 2023

NADA’s new Welfare and Sports Club Committee formed

3 March 2023

NADA gratitude towards the former Chief Secretary, MOHA.

20 February 2023

Walkabout NADA Kelantan meets visitors at Siti Khadijah Market

19 February 2023

Roadshow: Head Office unveils Road tour campaign across the country

19 February 2023

Director General ‘work visit’ to NADA office Machang District

18 February 2023
Page1 Page2 Page3 Page4 Page5
MEDIA GALLERY
  • Photo Gallery
  • Video Gallery
  • Photo Gallery
  • Video Gallery
REPORTS & STATISTICS
  • Drugs Statistics
  • Activity Report Statistics
  • Social Media Reports
  • Online Service Reports
  • Client Charter Achievement Reports
  • Drugs Statistics
  • Activity Report Statistics
  • Social Media Reports
  • Online Service Reports
  • Client Charter Achievement Reports
SOURCE & REFERENCES
  • NADA’s News
  • Recognition
  • User Manual Online Help
  • NADA’s News
  • Recognition
  • User Manual Online Help
laman Web QRCode

NATIONAL ANTI-DRUGS AGENCY  MALAYSIA
MINISTRY OF HOME AFFAIRS
Jalan Maktab Perguruan Islam
43000 Kajang, Selangor

Tel : 03 – 8911 2200
Fax : 03 – 8926 2055
E-mail : webmaster[at]adk[dot]gov[dot]my

 AADK Hotline: 1-800-22-2235 / 019 – 626 2233

laman Web QRCode
REFERENCES
  • RSS Feed
  • Sitemap
  • Disclaimer
  • Privacy Policy
  • Security Policy
  • Electronic Archives
  • Credit

Updated :

  • March 20, 2023

Our Visitor

2501582
Total views : 3277899
March 22, 2023

©2021 National Anti-Drugs Agency, All Rights Reserved.
Best viewed using Mozilla Firefox 3, Internet Explorer 11, and Google Chrome with minimum resolution.

X